<!DOCTYPE html>
<html class="no-js">

<head>
	<meta charset="utf-8">
	<meta http-equiv="X-UA-Compatible" content="IE=edge">
	<title>CÁNCER DE PULMÓN</title>
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<meta name="description" content="CÁNCER DE PULMÓN" />
	<meta name="keywords" content="cancer de pulmon, oncologia, medicina" />
	<meta name="author" content="e-oncologia" />

	<link rel="shortcut icon" type="image/png" href="images/logo.png" />

	<link href="https://fonts.googleapis.com/css?family=Open+Sans&display=swap" rel="stylesheet">
	<link href='https://fonts.googleapis.com/css?family=Montserrat:400,700' rel='stylesheet' type='text/css'>

	<link rel="stylesheet" href="css/animate.css">
	<link rel="stylesheet" href="css/icomoon.css">
	<link rel="stylesheet" href="css/bootstrap.css">
	<link rel="stylesheet" href="css/owl.carousel.min.css">
	<link rel="stylesheet" href="css/owl.theme.default.min.css">
	<link rel="stylesheet" href="css/style.css">
	<script src="js/modernizr-2.6.2.min.js"></script>

</head>

<body>

	<div id="ico-page"><a href="#" class="js-ico-nav-toggle ico-nav-toggle"><i></i></a>
		<aside id="ico-aside" role="complementary" class="border js-fullheight" style="background-image: url(images/BGoscuro.jpg);">
			<p><br></p>
			<h2 id="ico-logo"><a href="index.html"><img src="images/logo.png" height="80"></a></h2>
			<nav id="ico-main-menu" role="navigation">
				<ul>
					<li><a href="m1u0.html"><span class="bgdestacado2">PRESENTACIÓN</a></li>
					<br>
					<li><a href="m1u1.html"><span class="bgdestacado2">1</span> ASPECTOS GENERALES</a></li>
					<br>
					<li><a href="m2u1.html"><span class="bgdestacado2">2</span> TTO. ESTADOS PRECOCES</a></li>
					<br>
					<li><a href="m3u1.html"><span class="bgdestacado2">3</span> ESTADIOS IIIA Y IIIB</a></li>
					<br>
					<li><a href="m4u1.html"><span class="bgdestacado2">4</span> TTO. ENFERMEDAD AVANZADA EN PRIMERA LÍNEA</a></li>
					<br>
					<li><a href="m5u1.html"><span class="bgdestacado2">5</span> TTO. ENFERMEDAD AVANZADA EN SEGUNDA LÍNEA</a></li>
					<br>
					<li><a href="m6u1.html"><span class="bgdestacado2">6</span> CÁNCER MICROCÍTICO DE PULMÓN</a></li>
					<br>
					<li><a href="m7u0.html"><span class="bgdestacado2">BIBLIOGRAFÍA</a></li>
				</ul>
			</nav>
		</aside>


		<div id="ico-main">

			<div class="ico-cabecera">
				<div class="ico-narrow-content animate-box">
					<h4 class="text-center">PRESENTACIÓN</h4>
					<img src="images/pulmonICONO1.png" alt="" class="img-responsive centrada">
				</div>
			</div>



			<div class="ico-narrow-content">
				<div class="row animate-box" data-animate-effect="fadeInLeft">
					<div class="col-md-12">
						<br>
						<h1>Bibliografía <span class="rosa">:</span></h1>
					</div>
				</div>
			</div>
			<div class="ico-narrow-content">
				<div class="row animate-box" data-animate-effect="fadeInLeft">
					<div class="col-md-12">
						<p class="marcoOSCURO"><span class="bgrosaclaro">Mountain CF</span> Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710- 1717</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">PORT Meta-analysis Trialists Group</span> Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998; 352:257-263.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Wang EH, Corso CD, Rutter CE et al.</span> Postoperative radiation therapy is associated with improved overall survival in incompletely resected stage II and III non–small-cell lung cancer. J Clin Oncol 2015;33:1-8.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Non-small Cell Lung Cancer Collaborative Group</span> Chemotherapy in non-small cell lung cancer: a meta- analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311:899-909.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Keller SM, Adak S, Wagner H, et al.</span> A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small cell lung cancer. N Engl J Med 2000; 343:1217-1222. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003; 95:1453-1461.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Waller D, Peake MD, Stephens RJ, et al.</span> Chemotherapy for patients with non-small cell lung cancer. The surgical setting of the Big Lung Trial. Eur J CardioThorac Surg 2004; 26:173-182.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">The International Adjuvant Lung Cancer Trial Collaborative Group</span> Cisplatin-based adjuvant chemotherapy in patients with completely resected non–small-cell lung cancer. N Engl J Med 2004;350:351-360.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Winton TL, Livingston R, Johnson D, et al.</span> Vinorelbine plus Cisplatin vs. Observation in Resected Non- Small-Cell Lung Cancer. N Engl J Med 2005; 352:2589-2597.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Douillard JY, Rosell R, De Lena M, et al.</span> Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7:719-727. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. J Clin Oncol 2008;26:3552-3559.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Strauss GM, Herndon JE, Maddaus MA, et al.</span> Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2008;26:5043-5051.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Kato H, Ichinose Y, Ohta M, et al.</span> A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350:171317-21.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Arriagada R, Dunant A, Pignon JP et al.</span> Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer J Clin Oncol 2010;28:35-42.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Butts CA, Ding K, Seymour L et al</span> Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10. J Clin Oncol 2010;28:29-34.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Depierre A, Milleron B, Moro-Sibilot D et al.</span> Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20:247-253.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Pisters KM, Ginsberg RJ, Giroux DJ et al.</span> Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 2000; 119:429- 439.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Pisters KM, Vallières E, Crowley JJ et al.</span> Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol 2010;28:1843-1849.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Felip E, Rosell R, Maestre JA et al.</span> Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer J Clin Oncol 2010;28:3138-3145.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Olaussen KA, Dunant A, Fouret P et al.</span> DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Scagliotti G, Hanna N, Fossella F et al.</span> The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies.The Oncologist 2009;14:253-263.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Goss GD, O’Callaghan C, Lorimer I et al.</span> Gefitinib versus placebo in completely resected non–small-   cell lung cancer: Results of the NCIC CTG BR19 Study. J Clin Oncol 2013;31:3320-3326.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Kelly K, Altorki NK, Eberhardt WEE et al.</span> Adjuvant erlotinib versus placebo in patients with stageIB-IIIA non–small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol 2015;33:4007-4014.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">26.Slotman BJ, van Tinteren H, Praag JO, et al.</span> Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2015; 385:36.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Provencio M et al., Randomized phase II trial (RENO):</span> efficacy results of oral vinorelbine or etoposide combined with cisplatin in chemo-radiotherapy treatment of locally advanced NSCLC (LA-NSCLC). SLCG 10/02. J Clin Oncol 34, 2016 (suppl; abstr 8538).</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Senan S, Brade A,Wang LH et al. PROCLAIM:</span> randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non–small-cell lung cancer. J Clin Oncol 2016; 34: 953–962.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Lindeman N, Cagle P, Aisner D et al.</span> Updated molecular testing guidelinefor the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med 2018; 142: 321–346.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Malvezzi M, Carioli G, Bertuccio P et al.</span> European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol 2017; 28: 1117–1123.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Dietel M, Bubendorf L, Dingemans AM et al.</span> Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax 2016; 71: 177–184.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Kalemkerian GP, Narula N, Kennedy EB et al.</span> Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol 2018; 36: 911–919.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Mok T, Carbone D, Hirsch F.</span> IASLC <a href="http://wclc2017.iaslc.org/">Atlas of EGFR testing in Lung cancer</a>. IASLC 2017.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Tsao M, Hirsch F, Yatabe Y.</span> IASLC Atlas of ALK and ROS1 Testing in Lung Cancer, Second Edition. Aurora, CO: International Association for the Study of Lung Cancer 2016.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Peters S, Camidge DR, Shaw AT et al.</span> Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017; 377: 829–838.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Lindeman NI, Cagle PT, Aisner DL et al.</span> Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol 2018; 13: 323–358.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Gainor JF, Dardaei L, Yoda S et al.</span> Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 2016; 6: 1118–1133.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Herbst RS, Baas P, Kim DW et al.</span> Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540–1550.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Brahmer J, Rodríguez-Abreu D, Robinson A et al.</span> OA 17.06 updated analysis of KEYNOTE-024: pembrolizumab vs platinum-based chemotherapy for advanced NSCLC with PD-L1 TPS 50%. J Thorac Oncol 2017; 12: S1793–S1794.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Lopes G, Wu Y-L, Kudaba I et al.</span> Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) 1%: Open-label, phase 3 KEYNOTE-042 study. J Clin Oncol 2018; 36(18 Suppl): LBA4.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Gandhi L, Rodriguez-Abreu D, Gadgeel S et al.</span> Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378: 2078–2092.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Socinski MA, Jotte RM, Cappuzzo F et al.</span> Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018; 378: 2288–2301.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Papadimitrakopoulou V, Cobo M, Bordon R et al.</span> IMPOWER132: PFS and safety results with 1L atezolizumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 19th World Conference on Lung Cancer 2018; abstr. OA05.07.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Paz-Ares LG, Luft A, Vicente D et al.</span> Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med 2018.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Jotte RM, Cappuzzo F, Vynnychenko I et al.</span> IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab þ carboplatin þ paclitaxel or nab-paclitaxel vs carboplatin þ nabpaclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol 2018; 36(18 Suppl): LBA9000.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Rittmeyer A, Barlesi F, Waterkamp D et al.</span> Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Lancet</span> 2017; 389: 255–265.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Mok TSK, Kim S-W, Wu Y-L et al.</span> Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses. J Clin Oncol 2017; 35: 4027–4034.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Park K, Tan EH, O’Byrne K et al.</span> Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 2016; 17: 577–589.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Paz-Ares L, Tan EH, O’Byrne K et al.</span> Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 2017; 28: 270–277.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Wu YL, Cheng Y, Zhou X et al.</span> Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18: 1454–1466.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Mok TS, Cheng Y, Zhou X et al.</span> Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol 2018; 36: 2244–2250.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Soria JC, Ohe Y, Vansteenkiste J et al.</span> Osimertinib in untreated EGFRmutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378: 113–125.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Nakamura A, Morita S, Hosomi Y et al.</span> Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). J Clin Oncol 2018; 36(Suppl): abstr 9005.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Yamamoto N, Seto T, Nishio et al.</span> Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutationpositive non-squamous non-small-cell lung cancer (NSCLC): survival follow-up results of JO25567. J Clin Oncol 2018; 36(Suppl): abstr 9007.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Rosell R, Dafni U, Felip E et al.</span> Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med 2017; 5: 435–444.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Furuya N, Saito H, Watanabe K et al.</span> Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026. J Clin Oncol 2018; 36(Suppl): abstr 9006.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Mok TS, Wu YL, Ahn MJ et al.</span> Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376: 629–640. 196. Mok T, Ahn M-J, Han J-Y et al. CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: data from a randomized phase III trial (AURA3). J Clin Oncol 2017; 35: 9005.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Soria JC, Tan DSW, Chiari R et al.</span> First-line ceritinib versus platinumbased chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 2017; 389: 917–929.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Cho BC, Kim DW, Bearz A et al.</span> ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol 2017; 12: 1357–1367.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Hida T, Nokihara H, Kondo M et al.</span> Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 2017; 390: 29–39.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Camidge DR.</span> Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALKþ NSCLC. J Clin Oncol 2018; 35(Suppl): 9064.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Shaw AT, Kim TM, Crino L et al.</span> Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2017; 18: 874–886.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Novello S, Mazieres J, Oh IJ et al.</span> Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive nonsmall-cell lung cancer: results from the phase III ALUR study. Ann Oncol 2018; 29: 1409–1416.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Hochmair MJ, Tiseo M, Reckamp KL et al.</span> 97P Brigatinib in crizotinibrefractory ALKþ NSCLC: updates from the pivotal randomized phase 2 Trial (ALTA). Ann Oncol 2017; 28(Suppl 2): ii28–ii5.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Shaw AT, Felip E, Bauer TM et al.</span> Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol 2017; 18: 1590–1599.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Shaw AT, Martini J-F, Besse B et al.</span> Abstract CT044: efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations. Cancer Res 2018; 78: CT044.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Felip E, Bauer T, Solomon B et al.</span> MA07.11 safety and efficacy of lorlatinib (PF-06463922) in patients with advanced ALKþ or ROS1þ nonsmall- cell lung cancer (NSCLC). J Thorac Oncol 2017; 12: S383–S384.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Shaw AT, Bauer TM, Takahashi T et al.</span> 1380TiP A randomized, openlabel comparison of lorlatinib versus crizotinib as first-line treatment for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. Ann Oncol 2017; 28(Suppl 5): v460–v496.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Camidge DR, Kim HR, Ahn M-J et al.</span> Brigatinib versus crizotinib in ALK-positive non–small-cell lung cancer. N Engl J Med 2018.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Planchard D, Smit EF, Groen HJM et al.</span> Updated survival of patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D þ trametinib (T) in the phase II BRF113928 study. J Clin Oncol 2017; 28(Suppl 5): 9075.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Planchard D, Smit EF, Groen HJM et al.</span> Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017; 18: 1307–1316.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Lee SH, Lee JK, Ahn MJ et al.</span> Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Ann Oncol 2017; 28: 292–297.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Yoh K, Seto T, Satouchi M et al.</span> Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med 2017; 5: 42–50.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Drilon AESV, Oxnard GR et al.</span> A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. J Clin Oncol 2018; 36(Suppl); abstr 102.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Spigel DR, Edelman MJ, O’Byrne K et al.</span> Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: mETLung. J Clin Oncol 2017; 35: 412–420.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Awad MM, Leonardi GC, Kravets S et al.</span> Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC). J Clin Oncol 2017; 35: 8511.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Li BT, Shen R, Buonocore D et al.</span> Ado-trastuzumab emtansine for patients with HER2 mutant lung cancers: results from a phase II basket trial. J Clin Oncol 2018; 36: 2532–2537.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Drilon A, Siena S, Ou SI et al.</span> Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1).</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Cancer Discov</span> 2017; 7: 400–409.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Drilon A, Laetsch TW, Kummar S et al.</span> Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N Engl J Med 2018; 378: 731–739.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Temel JS, Greer JA, El-Jawahri A et al.</span> Effects of early integrated palliative care in patients with lung and GI cancer: a randomized clinical trial. J Clin Oncol 2017; 35: 834–841.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Horn L, Spigel DR, Vokes EE et al.</span> Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: twoyear outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 2017; 35: 3924–3933.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Faivre-Finn C, Snee M, Ashcroft L, et al.</span> Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 2017; 18:1116.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC)</span> First report of a randomized expansion cohort from CheckMate 032. J Clin Oncol 2018; 35S: ASCO #8503.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Chung HC, Lopez-Martin JA, Kao S C-H, et al.</span> Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. J Clin Oncol 2018; 36S: ASCO# 8506.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Ott PA, Elez E, Hiret S, et al.</span> Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol 2017; 35:3823.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Horn L, Mansfield AS, Szczęsna A, et al.</span> First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 2018; 379:2220.</p>
					</div>
				</div>
			</div>
			
			

			
		




	
		

			

		



		


		
		

			

			

			

		
					

		

		

		









			<div class="ico-cabecera">
				<div class="ico-narrow-content">
					<div class="pager">
						<br>
					</div>
				</div>
			</div>










		</div>
	</div>

	<!-- jQuery -->
	<script src="js/jquery.min.js"></script>
	<!-- jQuery Easing -->
	<script src="js/jquery.easing.1.3.js"></script>
	<!-- Bootstrap -->
	<script src="js/bootstrap.min.js"></script>
	<!-- Carousel -->
	<script src="js/owl.carousel.min.js"></script>
	<!-- Stellar -->
	<script src="js/jquery.stellar.min.js"></script>
	<!-- Waypoints -->
	<script src="js/jquery.waypoints.min.js"></script>
	<!-- Counters -->
	<script src="js/jquery.countTo.js"></script>
	<!-- MAIN JS -->
	<script src="js/main.js"></script>
	<!-- partial -->
	<script src='https://cdnjs.cloudflare.com/ajax/libs/vue/2.5.13/vue.min.js'></script>
	<script src="js/scriptdiagram.js"></script>

</body>

</html>
